Send to a Friend Font Size: Increase Decrease

AURA and H1ZN34 Related Headlines

May 4, 2026 06:01AM Aura Biosciences names Natalie Holles CEO as phase 3 trial nears completion
May 4, 2026 06:01AM Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

AURA and H1ZN34 Related Press Releases

May 4, 2026 06:01AM Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

AURA and H1ZN34 Related SEC Filings